Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

Declining NAD+ levels have been linked to aging-associated pathologies. Here the authors present results of a double-blind, randomized crossover trial on 30 healthy middle-aged individuals to show that nicotinamide riboside effectively elevates NAD+ levels in humans, appears to be well tolerated, an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christopher R. Martens, Blair A. Denman, Melissa R. Mazzo, Michael L. Armstrong, Nichole Reisdorph, Matthew B. McQueen, Michel Chonchol, Douglas R. Seals
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/c9be7355fafc4bd8a56ea5d212f30477
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c9be7355fafc4bd8a56ea5d212f30477
record_format	dspace
spelling	oai:doaj.org-article:c9be7355fafc4bd8a56ea5d212f304772021-12-02T17:33:00ZChronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults10.1038/s41467-018-03421-72041-1723https://doaj.org/article/c9be7355fafc4bd8a56ea5d212f304772018-03-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-03421-7https://doaj.org/toc/2041-1723Declining NAD+ levels have been linked to aging-associated pathologies. Here the authors present results of a double-blind, randomized crossover trial on 30 healthy middle-aged individuals to show that nicotinamide riboside effectively elevates NAD+ levels in humans, appears to be well tolerated, and may have potential to improve cardiovascular parameters.Christopher R. MartensBlair A. DenmanMelissa R. MazzoMichael L. ArmstrongNichole ReisdorphMatthew B. McQueenMichel ChoncholDouglas R. SealsNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Christopher R. Martens Blair A. Denman Melissa R. Mazzo Michael L. Armstrong Nichole Reisdorph Matthew B. McQueen Michel Chonchol Douglas R. Seals Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
description	Declining NAD+ levels have been linked to aging-associated pathologies. Here the authors present results of a double-blind, randomized crossover trial on 30 healthy middle-aged individuals to show that nicotinamide riboside effectively elevates NAD+ levels in humans, appears to be well tolerated, and may have potential to improve cardiovascular parameters.
format	article
author	Christopher R. Martens Blair A. Denman Melissa R. Mazzo Michael L. Armstrong Nichole Reisdorph Matthew B. McQueen Michel Chonchol Douglas R. Seals
author_facet	Christopher R. Martens Blair A. Denman Melissa R. Mazzo Michael L. Armstrong Nichole Reisdorph Matthew B. McQueen Michel Chonchol Douglas R. Seals
author_sort	Christopher R. Martens
title	Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
title_short	Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
title_full	Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
title_fullStr	Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
title_full_unstemmed	Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
title_sort	chronic nicotinamide riboside supplementation is well-tolerated and elevates nad+ in healthy middle-aged and older adults
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/c9be7355fafc4bd8a56ea5d212f30477
work_keys_str_mv	AT christopherrmartens chronicnicotinamideribosidesupplementationiswelltoleratedandelevatesnadinhealthymiddleagedandolderadults AT blairadenman chronicnicotinamideribosidesupplementationiswelltoleratedandelevatesnadinhealthymiddleagedandolderadults AT melissarmazzo chronicnicotinamideribosidesupplementationiswelltoleratedandelevatesnadinhealthymiddleagedandolderadults AT michaellarmstrong chronicnicotinamideribosidesupplementationiswelltoleratedandelevatesnadinhealthymiddleagedandolderadults AT nicholereisdorph chronicnicotinamideribosidesupplementationiswelltoleratedandelevatesnadinhealthymiddleagedandolderadults AT matthewbmcqueen chronicnicotinamideribosidesupplementationiswelltoleratedandelevatesnadinhealthymiddleagedandolderadults AT michelchonchol chronicnicotinamideribosidesupplementationiswelltoleratedandelevatesnadinhealthymiddleagedandolderadults AT douglasrseals chronicnicotinamideribosidesupplementationiswelltoleratedandelevatesnadinhealthymiddleagedandolderadults
_version_	1718380088170381312

Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

Ejemplares similares